Kevin Doyle

Kevin is an experienced drug hunter, with over 20 years in the industry encompassing biotech, pharma and CROs. He has led successful teams and driven major strategic collaborations, in a variety of different therapeutic areas. These collaborations have been all along the drug discovery gamut, from hit finding activities to lead optimisation programmes that have successfully delivered compounds into pre-clinical and clinical settings. 

Prior to joining Cancer Research Horizons, he led the medicinal chemistry efforts at Cerevance, a biotech based in Cambridge focussing on novel targets for neurodegeneration. Kevin is the co-author/co-inventor on over 40 scientific papers and patents.